Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse.

Détails

ID Serval
serval:BIB_79D9D55EB1CB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse.
Périodique
Clinical oncology
Auteur⸱e⸱s
Kinj R., Doyen J., Hannoun-Lévi J.M., Naghavi A.O., Chand M.E., Baudin G., Ferrero J.M., François E., Evesque L., Borchiellini D., Benezery K., Bondiau P.Y.
ISSN
1433-2981 (Electronic)
ISSN-L
0936-6555
Statut éditorial
Publié
Date de publication
01/2021
Peer-reviewed
Oui
Volume
33
Numéro
1
Pages
e15-e21
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Up to 40% of patients who have received radiation for a pelvic malignancy will develop locoregional recurrence in the previously irradiated volume. Stereotactic body radiotherapy (SBRT) has been used in the oligometastatic setting, and provides an ablative approach ideal for reirradiation. The purpose of this study was to evaluate the outcomes after SBRT reirradiation of extraosseous recurrences in the pelvis.
This single institution retrospective study evaluated patients treated with SBRT reirradiation in the pelvis from January 2011 to February 2018. Patients with more than five oligometastatic lesions, >7 cm in size, and recurrence within the prostate were excluded.
In total, 30 patients were treated with SBRT with a median follow-up of 29.4 months. The primary tumour sites were most commonly rectum (30.8%) and prostate (30.8%). The median time interval between irradiation for the primary and SBRT reirradiation was 48 months (3-245). The typical reirradiation treatment was 35 Gy in five fractions, the median gross tumour volume size was 10.2 (0.3-110.5) ml and the most common target was the iliac nodes (40%). There were three (10%) acute grade 3 toxicities and no late grade 3 or more toxicities. At 12/24 months, local relapse-free survival, metastasis-free survival, progression-free survival and overall survival were 67.7%/50.7%, 67%/41.7%, 34.8%/14.9% and 83.2%/62.5%, respectively. On univariate analysis, improved local control was associated with low gross tumour volume (<10 ml) (P = 0.003) and prostate primary (P = 0.02), but was no longer significant on multivariate analysis. The proximity of organ at risk to the target did not significantly correlate with worse toxicity (P = 0.14) or tumour coverage (gross tumour volume: P = 0.8, planning target volume: P = 0.4).
SBRT pelvic reirradiation in oligometastatic patients is a safe and effective treatment modality. Careful consideration should be taken with larger tumour size, as it may be associated with worse oncological and toxicity outcome.
Mots-clé
Pelvic radiotherapy, pelvic reirradiation, reirradiation, stereotactic radiotherapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/07/2020 10:55
Dernière modification de la notice
20/07/2021 5:39
Données d'usage